Clinical use of genome-wide sequencing (GWS) requires pre-test genetic counseling, but the availability of genetic counseling is limited. We developed an interactive online decision-support tool, DECIDE, to make genetic counseling, patient education, and decision support more readily available. We performed a non-inferiority trial comparing DECIDE to standard genetic counseling to assess the clinical value of DECIDE for pre-GWS counseling. One hundred and six parents considering GWS for their children with epilepsy were randomized to conventional genetic counseling or DECIDE. Following the intervention, we measured parents' knowledge and empowerment and asked their opinions about using DECIDE. Both DECIDE and conventional genetic counseling significantly increased parents' knowledge, with no difference between groups. Empowerment also increased but by less than 2% in each group. Parents liked using DECIDE and found it useful; 81% would recommend it to others; 49% wished to use it along with a genetic counselor; 26% of parents preferred to see a genetic counselor; 7% preferred DECIDE alone; and 18% had no preference. DECIDE appears equivalent to genetic counseling at conveying information. In addition, it was highly acceptable to the majority of study participants, many of whom indicated that it was useful to their decision-making. Use of DECIDE as a pre-test tool may extend genetic counseling resources.
Introduction
Use of genome-wide sequencing (GWS) is increasing in clinical genetics and in a variety of other medical specialties (Bowdin et al. 2016) . Genetic counseling is an essential prerequisite to GWS to ensure that patients have an understanding of its benefits, risks, and possibilities for uncertain results before choosing the test for themselves or their family (Boycott et al. 2015; Green et al. 2013 ). Furthermore, it is critical that individuals base their decision in the context of their own personal values. However, genetic counseling is not always available to families considering GWS due to constraints of time, geography, or availability of genetic counseling personnel.
A North American shortage of genetic counselors and adequately trained clinicians with knowledge of GWS has long been predicted (Brunham and Hayden 2012; Roche 2012) and is now becoming apparent (Pain 2016) . It is therefore important to consider alternative methods to Shelin Adam and Patricia H. Birch contributed equally to this work.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10897-018-0281-1) contains supplementary material, which is available to authorized users. support patients' and families' GWS decision-making to ensure adequate and equitable access (Bowdin et al. 2016; Lewis et al. 2016) . Many have raised the need for innovative, web-based tools to assist in genetic counseling (Dimmock 2012) . BA practical concern is the shortage of genetic-counseling professionals. The need for accurate information will provide an impetus for increasing the genetics workforce-but may also inspire innovative models of information provision. One such approach may be a Web-based system…^ (Yurkiewicz et al. 2014) .
Decision aids, which integrate information provision with decisional support, are a compelling alternative or adjunct to conventional pre-GWS genetic counseling. They are effective when users are faced with complex and potentially difficult treatment or screening decisions in various areas of medicine (Sheehan and Sherman 2012) , including for genetic screening and single gene testing (Kuppermann et al. 2009; Wakefield et al. 2008; Yee et al. 2014) , and have been proposed for applications as complex as prenatal whole genome sequencing and newborn screening (Chen and Wasserman 2017; Lewis et al. 2016 ). An interactive decision aid that customizes information to each user's specific needs and interests promotes information retention and patient satisfaction (Friedman et al. 2011 ) and may empower patients regarding their healthcare decisions, particularly if the decision aid is tailored by the user (Staszewska et al. 2017; Syrowatka et al. 2016) . Compared to usual care, users of decision aids are better informed and have improved knowledge and more accurate understanding of the pros and cons of their options. Users typically participate to a greater extent in the decision, feel clearer about what matters to them, and may make choices that are more congruent with their values (Stacey et al. 2017) .
Guided by the International Patient Decision Aid Standards (Coulter et al. 2013) , we developed DECIDE, an interactive online educational tool and decision aid. Our aim was to create a tool to guide adult patients or parents of affected children towards a decision about whether or not to have diagnostic GWS. DECIDE has been fully described elsewhere (Birch et al. 2016) . In summary, it provides genomic testing information via a choice of media such as text or video, and at different levels of detail. It presents the pros and cons of sequencing, including issues of incidental findings (if they are returned or offered) and variants of unknown significance. DECIDE guides the user to weigh the pros and cons of GWS in the context of his or her own values and tailors the display of options to promote choices that are concordant with the user's informed goals and preferences (Bansback et al. 2014) . DECIDE then nudges the user towards a logical, but over-rideable decision, based on his or her identified values (Bansback et al. 2014) . It is designed for pre-test decisions about whole-genome sequencing, exome sequencing, or exomes analyzed as panels.
Before introducing any potential decision-support tool, however, it is important that it is thoroughly evaluated in a clinical setting, particularly in the emerging field of decisional science where evidence to guide implementation is still limited (Ekstract et al. 2017; Syrowatka et al. 2016) . As part of our evaluation of DECIDE, we performed a randomized trial to compare the effectiveness and acceptability of DECIDE to conventional genetic counseling, using a non-inferiority model, in families considering genomic testing for their child with early onset epilepsy.
Methods
Participants Participants for the trial described here were parents of children with early-onset (age ≤ 5 years) epilepsy of unknown cause participating in the study BPaediatric Epilepsy: Using Genomics to Improve Patient Care and Outcomes,^a clinical research study designed to assess the value of genomic testing. Typically, families in this study were well known to their neurologist clinicians (authors MD and MC) and the affected children had experienced many previous tests and interventions. The neurologists approached SA to provide genetic counseling to support parents' decision-making regarding exome sequencing for their child.
Procedures
In this study, potentially causative variants were validated using Sanger sequencing of the proband and the parents and a bioinformatic filter limited analysis to about 550 genes previously implicated in epilepsy.
Prior to genetic counseling or obtaining consent for genomic testing, informed consent via a signed consent form was obtained from parents to participate in the genetic counseling study reported here. Parents were randomized as a couple to receive one of the two interventions: either standard pre-test genetic counseling or DECIDE. Major outcomes of knowledge and empowerment (described later) were assessed at baseline and 1 week after the first intervention ( Fig. 1) .
A single individual (SA), experienced in genomic counseling, provided counseling to all subjects randomized to the genetic counseling intervention. This was typically in a one-hour appointment slot, arranged specifically for this counseling study. SA used a standardized checklist for each participant to ensure she discussed the same factual material, including the same pros and cons of the testing as contained in DECIDE. She referenced this checklist to ensure consistency across sessions. The checklist was developed to reflect the informational content of DECIDE, which in turn represents the counseling practices of our clinic. The study schedule was arranged with each family at the beginning of the study: SA met families in person, where possible, in a private clinic room within our tertiary care children's hospital. If an in-person appointment was too challenging to arrange for the family, then a one-hour telephone appointment was booked at a time convenient to the participant families. There was no financial incentive for participants, and all costs of testing were borne by the research study. Families received access to DECIDE via a secure server, through an individualized internet link, sent to them by email. They had to work through the decision-aid but could spend as much or as little time on it as they wished.
One week after the first intervention of either standard genetic counseling or DECIDE, all participants completed the post-intervention questionnaires. A week subsequent to this, they were provided the opposite intervention. Again, those receiving genetic counseling had the option of a telephone session. One week after this second intervention, they were given a set of usability and preference questions to enable them to compare the two methods. All questionnaires were distributed via an automated email link. (Online Resource S1).
Although both parents were invited to use DECIDE and to attend the genetic counseling session, only one parent's questionnaire responses were analyzed for each family. Where both parents completed the questionnaires, one was chosen at random for inclusion in the analysis. The study was approved by the University of British Columbia Research Ethics Board.
Outcome Measures
The two outcome measures chosen were an objective assessment of parents' knowledge of genome-wide testing and related concepts, and a subjective assessment of parents' empowerment. Parents' knowledge was chosen as the primary outcome because it is an essential component of any informed decision (Boycott et al. 2015; Feudtner et al. 2014) . Knowledge was measured using the GWS-KQ, which consists of 19 multiple-choice questions that mirror the educational goals of both interventions and was designed to assess parents' understanding of diagnostic GWS and its possible consequences. Examples of topics include definitions of genome and of variants of unknown significance and the likelihood of obtaining a genetic diagnosis via GWS. GWS-KQ has good test-retest reliability (r = 0.88), and internal consistency (Cronbach's α = 0.83). The questionnaire, information on scoring it, and additional psychometric data are provided in Online Resource S2.
Empowerment is a patient-centric concept (McAllister et al. 2011a ) describing the degree to which a patient or parent believes that he or she has decisional, cognitive, and behavioral control, emotional regulation, and hope (McAllister et al. 2011b ). We chose this empowerment measure for its ability to encompass and quantify the supportive and emotional benefits of genetic counseling (McAllister and Dearing 2015) . A genetic counseling-specific measure of empowerment has been shown to be positively correlated with more general measures of well-being, such as internal health locus of control, perceived personal control, and satisfaction with life (McAllister et al. 2011b ). We assessed empowerment using the GCOS-24 (McAllister et al. 2011b ), a validated 24question instrument, with each question rated on a sevenpoint Likert scale and total scores ranging from 24 (low) to 168 (high empowerment). GCOS-24 has been shown to be sensitive to changes in state after genetic counseling (Inglis et al. 2015) .
Both GWS-KQ and GCOS-24 were measured by self-reported, online questionnaires at study entry and again, via an automated emailed link, 1 week after the intervention (Fig. 1) . To the best of our knowledge, GCOS-24 has not been used to measure potential effects of on-line decisional support tools, such as DECIDE.
Sample Size
Using data from a study of GWS-KQ in a sample of parents drawn from a similar, previously counseled population, we estimated the required sample size based on the expected improvement in knowledge from genetic counseling. Postgenetic counseling scores in GWS-KQ pilot studies (Online Resource S2) had a mean of 10.8 (standard deviation of 4.2). We therefore used a non-inferiority calculation, with a difference of one half of a standard deviation (equivalent to about 11% difference in knowledge score results), giving a recruitment goal of 50 participants per arm for 80% power for the primary outcome of knowledge (Sealed Envelope Ltd. 2012). Data from Inglis and colleagues' pre-and post-genetic counseling assessments of empowerment using GCOS-24
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Baseline: GCOS-24; GWS-KQ Usability quesƟons Fig. 1 Genetic counseling study design. Knowledge and empowerment were measured at baseline, then parents were randomized to use DECIDE or to receive standard genetic counseling (week 1). Parents' knowledge and empowerment were then reassessed (week 2). Parents received the opposite intervention (week 3) prior to receiving questions on the usability of DECIDE (week 4) (Inglis et al. 2015) , dictates that this sample size would provide a non-inferiority limit of 8.5 (equivalent to about a 6% difference in score results).
Data Analysis
Descriptive statistics, paired t tests, and analysis of covariance were performed with R version 3.3.1 (R Core Team 2013). Differences between genetic counseling and DECIDE means for baseline-adjusted change in score represent the best estimate of the true difference between change for the two arms (Vickers and Altman 2001) . We used analysis of covariance to adjust the post-intervention score for differences in baseline score. This is necessary to account for the expected negative correlation between baseline score and the size of the postintervention score increase (see also Online Resource S3, Figs. 1-4 ). Possible differences between telephone and inperson counseling sub-groups were compared using twotailed t tests.
Results
We enrolled 136 patients into the study BPaediatric Epilepsy: Using Genomics to Improve Patient Care and Outcomes.^Four families without computers and seven families not fluent in English were excluded from the genetic counseling trial. Another four families chose not to participate. The 121 remaining families were randomized prior to intervention (Fig. 1) . Three participants dropped out after randomization and nine after the baseline questionnaires; three were excluded for completing questionnaires at the wrong time point. The frequent reasons for dropout were Bno time^or acute illness or hospitalization of the child. All families who dropped out received standard genetic counseling prior to genomic testing.
Families
One hundred and six families provided complete data, and one parent was randomly selected for analysis when both parents provided data. In the analysis group, 81% of respondent parents were 30-50 years of age, and 48% had at least an undergraduate university degree. Parents described themselves as the biological mother (84%) or father (15%), with one foster mother. Parents described their families as complete in 70% of cases. The affected child was the only child in 21% of families. Children were under the age of 10 years for 63% of participants (age range 0 to 29 years; median 7 years) at the time of enrollment. Additional demographic data are provided in Online Resource S4. The parents in the genetic counseling arm were counseled either in-person (n = 31) or by telephone (n = 23). Of the 52 families who received genetic counseling as the second intervention, 31 received in-person counseling and 21 received telephone counseling.
GWS-KQ and GCOS-24 Scores
There were no statistical differences in pre-or post-counseling knowledge or empowerment scores, or in the change in scores, between subjects who received genetic counseling in person or by telephone. Improvement in knowledge in the inperson and telephone counseling groups was 4.3 and 4.2 points respectively (p = 0.97); increase in empowerment was 4.0 and 3.0 respectively (p = 0.76). Data for the telephone and in-person sub-groups were therefore combined for the genetic counseling intervention in all subsequent analyses.
Mean knowledge (GWS-KQ) and empowerment (GCOS-24) scores for the baseline and post-intervention time points are shown in Table 1 . Knowledge scores on the 19-point GWS-KQ scale increased over baseline by approximately 4 points following either genetic counseling or DECIDE (p < 0.001 for improvement in each group). Empowerment scores on the 144-point GCOS-24 scale also increased over baseline by about 3 points (p < 0.05 for each group).
There was no statistical difference between subjects who received genetic counseling and those who used DECIDE in either knowledge or empowerment gained. The baselineadjusted difference in knowledge gained between the two arms was 0.29 points (95% confidence interval − 0.74 to 1.32). The baseline-adjusted difference between the two arms for increase in empowerment was 1.9 points (95% confidence interval − 2.1 to 5.9). (Also see Online Resource S3, Figs. 1-4 .)
User Experience Data
The user preference questions were answered by 85 participants: 41 in the DECIDE arm and 44 in the standard genetic counseling arm. (See Online Resource S1 for questions and raw data.) The general consensus was positive: only one person would not recommend DECIDE to other families; 81% said they would recommend it, while 18% had no opinion. Forty-nine percent of participants said they would prefer to use DECIDE along with a genetic counselor; 26% would prefer to see a genetic counselor; 7% would prefer to use DECIDE; and the remainder (18%) had no preference. Reasons for preferring a genetic counselor included the personal interaction, having specific questions answered, and preferred learning style. The reasons given for preferring DECIDE were learning style and that it saved time. DECIDE typically takes between 10 and 45 min to complete, depending on users' choices.
Of the 42 people wishing to use DECIDE along with a genetic counselor, 55% would like to use DECIDE first, 17% would like to see a genetic counselor first, and the others had no preference. The main reasons stated for preferring to use DECIDE prior to genetic counseling were to obtain a basic understanding of the issues, after which more informed, specific questions could be asked of the genetic counselor. Preference did not appear to be associated with the actual order in which participants experienced DECIDE and genetic counseling.
Of the 12 general comments about DECIDE, seven were favorable (e.g., Bawesome,^BI really liked how the DECIDE tool took me through a self-evaluation of why I am choosing to take the genetic testing^), three made suggestions for improvement (e.g., add an option to indicate that the user is unclear; add infographics), and two restated their preference for in-person counseling.
Of the 85 respondents, 12 showed DECIDE to someone else: seven to a spouse, three to other family members, and two not stated. Fourteen participants returned to look at DECIDE after completing it the first time, and 57 said they would likely return to it in the future.
Although DECIDE provides users with the option to contact a genetic counselor with questions or concerns at any point through the decision process, none of the study participants utilized this option. However, all of the participants in this study either had already had a session with a genetic counselor or were aware that they would have a session with a genetic counselor during the study.
Discussion
This randomized trial was conducted with families considering genomic testing for their child with early onset epilepsy, to compare the effectiveness and acceptability of an online decision-aid, DECIDE, to conventional genetic counseling, using a non-inferiority model.
Parents who used DECIDE or received standard genetic counseling exhibited improved knowledge about GWS and its implications. There was no difference between the two groups in the amount of knowledge gained. This finding is consistent with observations that decision-support tools used in many other clinical contexts are as effective as in-person counseling at promoting knowledge acquisition (Stacey et al. 2017) .
Both groups also exhibited increased empowerment scores, with a similarly small increase in each arm. The increase of only 2% over baseline in each arm, although statistically significant, is probably not clinically meaningful. The only previously published study to document pre-and post-genetic counseling GCOS-24 scores demonstrated an 11% postcounseling increase in relatives of individuals with mental illness (Inglis et al. 2015) . Using data from this study, our sample size was overpowered to detect such a difference. We do not know the effect of disease type, severity, acuity, or parental stress on empowerment, but it is possible that the pressures of caring for a severely ill child and the desire to find out the cause of the condition, greatly outweigh any possible concerns about genomic testing and any empowering benefit from the genetic counseling or DECIDE itself. We chose empowerment as a secondary outcome because we believe it to be a measure of the supportive and emotional benefits of genetic counseling, anticipating that it might differentiate DECIDE from personal counseling. We conclude that there is no meaningful change in empowerment in either arm of the study or between arms. In the future, measures such as anxiety (Spielberger et al. 1977) , decisional regret (Brehaut et al. 2003) , or a multi-dimensional measure of informed choice (Lewis et al. 2016; Michie et al. 2002 ) may provide more 3.0 (9.0) Baseline-adjusted change scores 1.9 (− 2.1 to 5.9) 0.3 *Gain in knowledge from baseline is statistically significant after intervention in each arm (p < 0.001) **Gain in empowerment from baseline is statistically significant after intervention in each arm (DECIDE: p = 0.02; genetic counseling: p = 0.04) nuanced metrics of DECIDE's effectiveness and a better understanding of the entire decision-making process for diagnostic GWS among parents of seriously ill children and those undergoing GWS for other reasons.
Study Limitations
Whereas we deliberately chose to use a single genetic counselor for this study to ensure consistency, this may also limit the generalizability of our findings to other genetic counselors with different counseling styles. The generalizability of our conclusions is also limited by the fact that most of the participants were well-educated parents of children who were often quite ill. About 10% of families were excluded from the study due to lack of computer access or low English fluency. Some studies suggest that Internet based-technologies may be problematic for people with linguistic challenges and those with lower education (Hartz et al. 2017) , whereas others have found that knowledge gained by such tools is not related to either education level, health literacy, or e-health literacy (Yee et al. 2014) . Neither health literacy nor computer literacy was assessed in our study. These and other social, psychological, or experiential factors might, in the future, help to predict which families would particularly benefit from seeing a genetic counselor in person, but this would require a much larger study.
Of the 106 families, only one family in each arm declined GWS. It is likely that many parents who entered the study had decided to have GWS before either intervention, but we did not ask about this. We therefore cannot assess the full effect of our interventions on parents' choice to have their child undergo genomic testing. Anecdotally, in our clinic's experience with families counseled prior to GWS for other reasons, it is equally uncommon for families to decline GWS. In clinics where the rate of declining GWS is higher, the efficacy of DECIDE would need to be re-evaluated in that sub-sample.
Practice Implications
The need to make genetic counseling more widely available has been repeatedly raised (Lewis et al. 2016; Wynn 2016) , and Sweet et al. (2017) proposed assessing patient preferences for mode of communication of genetic counseling information. This study demonstrates the value of DECIDE to provide one innovative approach to the provision of pre-test information and decision support. While, we are unable to conclude that we adequately measured parent empowerment, DECIDE does appear to result in knowledge gain that is similar to that from standard genetic counseling sessions. Most importantly for future use, DECIDE appears to be highly acceptable to the majority of users, many of whom indicated that it was useful to their decision-making.
In the current study, we did not attempt to compare time spent by the genetic counselor in each arm because the design required that we provide identical genetic counseling content for all participants. Although we have no evidence that this would save any genetic counseling time, most participants stated that they would like to use DECIDE prior to genetic counseling. This might facilitate a more targeted or effective genetic counseling session.
Providing families with access to DECIDE may be particularly useful where availability of genetic counseling is limited, such as in medical specialty clinics without ready access to a genetic counselor and in rural or remote locations. Further, although there are already examples of online tools for result dissemination (Lewis et al. 2016; Tabor et al. 2017) , it is timely to assess interactive pre-GWS decision aids to ensure that widespread use of GWS is accompanied by appropriate patient education and decision support.
Research Recommendations
Studies employing additional outcome measures, and with a broader sample of patients and genetic counselors, are needed to define the clinical circumstances in which online educational tools and decision aids are most appropriate as adjuncts to, or replacements for, conventional genetic counseling. DECIDE is freely available by contacting the authors. A demonstration version is available here: http://bit.ly/DECIDE-EG.
Conclusions
This study provides initial evidence that an online decision-aid for genome-wide sequencing is non-inferior to in-person genetic counseling. DECIDE appears to be an effective and acceptable tool for the majority of parents considering diagnostic GWS for children suspected of having serious genetic diseases. Its use prior to undergoing diagnostic GWS may extend or target genetic counseling resources when used as an adjunct to, or replacement for, genetic counselors.
